elevated tumor content of both CEA and VEGF had a negative prognostic value in respect to either relapse-free (logrank test: 10.4, p = 0.001) or overall survival (log-rank test: 7.33, p = 0.007). Conclusion: Tumor tissue VEGF and CEA content determination might add useful prognostic information in the management of patients with CRC.
Vascular endothelial growth factor (VEGF) is the predominant angiogenic factor in human cancer and its level of expression in colorectal cancer (CRC) -assessed by a variety of techniques including Northern blotting, immunohistochemistry, enzyme-linked immunoassays and/or reverse transcription polymerase chain reaction -has been shown to correlate with tumor development and progression, metastasis and/or tumor vascularity [1] [2] [3] [4] [5] [6] . In particular, it has been suggested that VEGF is upregulated in the progression from nonmalignant to malignant colon cancers [7] and that VEGF does play a role early in tumor development at the stage of adenoma formation [2] . Accordingly, it has been suggested that VEGF might be considered an independent prognostic factor for both relapse-free survival (RFS) and overall survival (OS) in patients with CRC [8] [9] [10] [11] [12] . Furthermore, a significant correlation has recently been reported between preoperative serum VEGF and carcinoembryonic antigen (CEA) levels in colon cancer [12] , and it has been suggested that the combination of high serum CEA and high serum VEGF levels measured 6 months postoperatively was significantly associated with poor survival compared to high serum CEA and low serum VEGF [13] .
We have recently demonstrated that the quantification of the actual VEGF content on protein extracts from tumor tissues may be of advantage over the determination of circulating VEGF levels [6] . Using a commercially available immunoassay to quantitate VEGF on whole protein extracts obtained from biopsies of histologically confirmed neoplastic tissues and corresponding mucosa, histologically confirmed as 'normal', we demonstrated that tissue VEGF content was higher in CRC tissue biopsies compared to corresponding normal mucosa. Furthermore, tumor VEGF content was associated with clinicopathological variables and had an independent prognostic value in respect to OS [6] .
The objectives of the current study were to investigate whether there was any relationship between VEGF and CEA content of tumors and corresponding normal mucosa tissues obtained from patients with primary CRC at the time of surgery, and to assess the prognostic significance of their combined measurement with respect to RFS and OS.
Patients and Methods

Patients
Sixty-nine consecutive patients (39 males, 30 females; mean age 62 8 11 years) with histologically diagnosed primary colorectal adenocarcinoma (6 in Dukes' stage A, 37 in stage B, 21 in stage C and 5 in stage D), treated at the Department of Surgery of the University of Rome Tor Vergata, entered into the study. No patient received neoadjuvant chemotherapy or radiation therapy before surgery. No patient received antiangiogenic agents at any time of the study. Curative surgery was performed in all patients, and simultaneous partial hepatectomy for single liver metastasis was performed in the 5 stage D patients with no residual metastatic tumor (R 0 ). Fifty (72%) of 69 patients were considered eligible for adjuvant therapy. In particular, 2 of 12 patients with stage B1 CRC accepted to be included in an adjuvant therapy protocol, whereas 3 of 25 stage B2 patients were not considered eligible due to advanced age or comorbidity. Adjuvant therapy was instituted in all stage C patients (n = 21) and first-line chemotherapy was instituted in the 5 stage D patients. Fifteen healthy donors (7 males, 8 females; mean age 56 8 10 years) undergoing endoscopy for screening and surveillance for gastrointestinal cancer served as controls.
Patients were followed from the time of diagnosis of primary tumor for at least 3 years after surgery or until time of recurrence (median follow-up 67.4 months, ranging from 14.6 to 153.1). All patients were generally reviewed at 3-month intervals during the first 2 years after surgery. Thereafter, the interval between visits was increased to 6 or 12 months in parallel with tumor stage. No patient was lost at follow-up. The study was performed under the appropriate institutional ethics approvals and in accordance with the principles embodied in the Declaration of Helsinki. Informed consent was obtained from each participating subject.
Sample Collection and Immunoassay
Multiple biopsies of histologically confirmed neoplastic tissues and mucosa (peeled from colonic wall approximately 10 cm distant to the tumor) histologically confirmed as normal were obtained at surgery, immediately frozen in liquid nitrogen and subsequently evaluated for VEGF and tumor marker content. Moreover, tissue biopsies of normal colorectal mucosa were obtained from healthy donors. All samples were shown to contain at least 80% of colonic mucosa cells. All carcinoma specimens were shown to be free of necrotic areas and to contain at least 50% malignant cells by histopathology. All specimens designated as normal mucosa from carcinoma patients contained at least 80% colonic mucosa. The quantitative evaluation of VEGF and tumor marker content in tissue was performed on whole protein extracts obtained from all the biopsies as previously described [6, 14, 15] .
Tissue VEGF (R&D Systems, Minneapolis, Minn., USA) and CEA (Abbott Labs, Chicago, Ill., USA) contents were determined using commercially available immunoassays, according to the manufacturers' instructions. VEGF determination was performed using a quantitative sandwich enzyme immunoassay technique with a monoclonal antibody specific for VEGF as the capture antibody and an enzyme-linked polyclonal antibody as the tracer. The assay recognizes both natural and recombinant human VEGF and does not exhibit cross-reactivity with a series of cytokines and growth factors. Intra-and interassay coefficients of variation are below 10%. The minimum detectable dose is lower than 9.0 pg/ml. Results were calculated from a standard curve using recombinant human VEGF in the range of 31.2-2,000 pg/ ml. CEA determination was performed using a two-step chemiluminescent microparticle immunoassay on an ARCHITECT i2000 system (Abbott Labs). The analytical sensitivity of the assay was calculated to be better than 0.5 ng/ml at the 95% level of confidence.
All protein extracts obtained from colorectal tissues were initially diluted with extraction buffer to a protein concentration of 1.0 mg/ml. The concentrations of VEGF and CEA in the tumor tissues and normal mucosas are expressed per milligram of protein. Measurements were done in a blinded fashion. All samples were assayed in duplicate and those showing values above the standard curve were serially diluted in protein-extraction buffer, and the test was repeated. The value for each sample was calculated as the mean of at least 2 determinations of 3 different biopsies from the same sample. Variability of VEGF content among the different biopsies ranged between 2 and 15% when positive. Negative results were confirmed as such in all 3 biopsies.
Statistical Analysis
Unless otherwise specified, data are presented as medians and interquartile ranges. Differences between groups were assessed by the Wilcoxon matched pairs test, Mann-Whitney U test and Kruskal-Wallis test. Univariate and multivariate analyses were performed by Cox's proportional hazards model: the first step was performed by the log-rank test, then the covariates found to be associated were included in Cox's regression model. For each variable the proportional hazard was tested. Clinical and laboratory variables considered in the analysis were: age, sex, site of primary tumor, grading, tumor size, lymph node involvement, VEGF and CEA tissue content. The variables that achieved statistical significance in the univariate analysis were subsequently included in a multivariate analysis using a Cox regression model. Only p values lower than 0.05 were regarded as statistically significant. All calculations were made using computer software packages (Egret, Cytel Software Co., Cambridge, Mass., USA and Statistica, StatSoft Inc., Tulsa, Okla., USA).
Results
Tissue VEGF and CEA contents of colorectal tissues from carcinoma lesions and corresponding normal mucosa of cancer patients, and from normal mucosa of healthy donors are summarized in table 1 . It is interesting to note that the VEGF (p ! 0.0001) and CEA (p ! 0.0001) contents of histologically normal mucosa from cancer patients are elevated compared with those of histologically normal mucosa from healthy donors, as previously reported [15] . Univariate correlation analysis showed the presence of a significant correlation between VEGF and CEA contents of colorectal tumor tissues (rho = 0.55, p ! 0.0001), corresponding normal mucosa (rho = 0.34, p ! 0.005) or normal mucosa of healthy donors (rho = 0.53, p ! 0.05; fig. 1 ).
General regression analysis was performed on tissue biopsies from CRC patients by forward stepping, including VEGF tissue content as the dependent variable and age, sex, grading, tumor size, nodal status, Dukes' stage of disease and CEA tissue content as independent variables. The results obtained demonstrated that CEA levels were the only independent predictor of VEGF tissue content either in CRC biopsies (regression coefficient = 0.57, p ! 0.0001) or normal mucosa (regression coefficient = 0.25, p = 0.037; tables 2 , 3 ).
Longitudinal follow-up was attained in all patients. Fifty-one (74%) of the 69 patients remained free of disease throughout a median follow-up of 76.3 months (ranging from 40.5 to 153.1), while 18 patients experienced recurrence of disease (4 in stage B, 11 in stage C, 3 in stage D; median follow-up: 37.7 months, ranging from 14.6 to 99.6). No differences were observed in age, sex and histotype or site of primary tumor between patients with and without recurrence.
Based on our previously published observations, VEGF and CEA tissue contents were categorized according to previously established cut-off values of 215 pg/mg of protein [6] and 300 ng/mg of protein [15] , respectively, based on the distribution of the antigen content of colorectal normal mucosa, yielding a specificity greater than 90%. Table 4 reports stage distribution, recurrence and mortality rates within groups of patients categorized on the basis of VEGF and CEA tumor content. As shown, Data are presented as medians with interquartile ranges in parentheses.
* Mann-Whitney U test: normal mucosa from CRC patients vs. that from healthy donors, p < 0.0001. patients with positive tumor tissue content of both variables, 13 (50%) relapsed within a median time of approximately 2 years. Eleven (85%) died after a median followup of 2.5 years, whereas 2 patients had surgery for a local recurrence or a single liver metastasis and were still alive 6 and 8 years, respectively, after initial diagnosis. Cox proportional hazards survival analysis was performed after applying a risk set stratification for the variable 'stage of disease' to the model. The results obtained showed that the presence of a positive tumor tissue content of both VEGF and CEA had an independent prognostic value in predicting both RFS (hazards ratio = 5.98, 95% confidence interval: 1.94-18.50, p = 0.002) and OS (hazards ratio = 4.73, 95% confidence interval: 1.52-14.72, p = 0.007), irrespective of stage of disease ( tables 5 , 6 ).
At a median follow-up of 76.3 months, 14 (20%) patients had died and 55 (80%) were still alive. Figures 2 and  3 show RFS and OS Kaplan-Meier curves for patients stratified according to VEGF and CEA tumor tissue content (VEGF/CEA -/-vs. VEGF/CEA +/-or -/+ vs. VEGF/CEA +/+) and Dukes' stage. Due to the limited sample size, it was not feasible to break down the survival curves for the evaluation of prognostic impact on VEGF/CEA within each Dukes' stage. Therefore, all subsequent analyses were performed after patients' stratification on Dukes' stages A + B vs. C + D. As shown in 
Discussion
Quantification of the tumor tissue VEGF content in CRC patients has been recommended in a previous study [6] . Here, we report evidences that tumor tissue VEGF and CEA content determination might add useful prognostic information in the management of patients with CRC. The finding that positive tumor tissue content of both VEGF and CEA had an independent prognostic value in predicting both RFS (p = 0.002) and OS (p = 0.007), irrespectively of stage of disease, provides the rationale for the use of novel biological variables in the definition of a subgroup of high-risk patients, which might benefit from stricter follow-up procedures and/or more aggressive treatment. The opportunity to gain prognostic information independently of classic histopathological staging may allow optimizing chemotherapeutic treatment which might not only negatively impact on quality of life and comorbidity, but also correspond to an increase in economic pressure on the national health system. This is particularly true for adjuvant chemotherapy whose use in patients with stage B disease remains controversial because of a lack of level I evidence [16, 17] . In fact, treatment recommendations from the American Society of Clinical Oncology for stage B colon cancer proposed in 2004 that there might be some 'patients with stage B disease that could be considered for adjuvant therapy, including patients with inadequately sampled nodes, T4 lesions, perforation, or poorly differentiated histology'. Similarly, in 2005, the minimum clinical recommendations, issued by the European Society for Medical Oncology, did not advocate the use of chemotherapy in stage B disease, but did state that chemotherapy 'may be considered in selected node-negative patients' [16] . Pilot studies indicated the potential clinical utility of serum VEGF levels in the palliative setting among CRC patients [18, 19] . In contrast, Berglund et al. [20] failed to demonstrate any prognostic and predictive value for VEGF and/or CEA serum levels, which did not provide any relevant clinical information for CRC patients. However, previous studies showed no correlation between CEA content in CRC tissues and serum CEA levels, suggesting that in considering diagnosis or potential therapies (such as anti-CEA recombinant vaccines) serum CEA levels should not be taken as an indicator of CEA expression in tumor lesions [15] .
Previous studies demonstrated that colon cancer patients with high level of tissue VEGF expression had an unfavorable outcome compared to patients with VEGFnegative tumors [5, 9, 21, 22] , but none of them has evaluated the prognostic value of VEGF in association with CEA tumor tissue content. In our analysis, positive VEGF/CEA patients displayed the worst prognosis both in terms of RFS and OS with 5-year survival rates similar to those of Dukes' stage C + D patients (48 vs. 46% and 65 vs. 65%, respectively). On the other hand, patients negative for both VEGF and CEA expression demonstrated the most favorable prognosis with 5-year RFS and OS rates of 100%.
Molecular testing of tumor tissues represents the most promising way to identify early stages patients who may need more aggressive approaches. According to our data, stratification of early stages colon cancer patients (Dukes' stages A and B) on the basis of VEGF and CEA tumor content determination can provide a useful tool in discriminating high-risk patients who might benefit from adjuvant treatment.
VEGF is the target of recently developed monoclonal antibodies that have expanded the armamentarium of treatment options for CRC patients. Conceptually, these newer agents are more scientifically appealing than older cytotoxic agents, as they more specifically target unique features of the cancer cells and their surroundings and so attempt to exploit the progress that has been made in the understanding of basic cell biology. The process of new blood vessel development, or angiogenesis, is being investigated for use in CRC patients to reduce growth and metastasis. Bevacizumab (Avastin TM ), a humanized monoclonal antibody targeting the circulating VEGF, was granted marketing authorization within the EU in January 2005 with the approved indication that 'Avastin (bevacizumab) in combination with intravenous 5-fluorouracil/folinic acid or intravenous 5-fluorouracil/folinic acid/irinotecan is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum' [23] . Although the contribution from this drug should not be denied, the therapeutic improvement is still small in absolute terms and comes at a price that will be difficult to handle in tax-funded health care systems [23] . The results obtained in this study suggest that combined measurement of tumor VEGF and CEA content might discriminate patients who can benefit from combination therapies. Trials are ongoing to evaluate the potential use of antiangiogenic drugs in the adjuvant setting (http:// www.clinicaltrial.gov).
Even though response to bevacizumab seems not to be related to the level of VEGF expression in metastatic patients [24] , in the adjuvant setting a different biological rationale can be considered. The prognostic impact of high levels of VEGF can be more relevant in the micrometastatic stage of the disease (that is in the adjuvant setting) when the neoangiogenic process is crucial for metastatic development. Similarly, bevacizumab activity can be more accurately predicted by evaluating VEGF tissue expression in this setting. Ongoing adjuvant studies including bevacizumab do not consider VEGF expression in the patient selection process, however, any effort to accurately select patients who really benefit from such expensive therapies is warranted. Thus, the possibility offered by the combined measurement of tumor VEGF and CEA content to identify a subgroup of patients at high risk of developing recurrent disease might be of utmost importance in selecting patients with early-stage CRC which may benefit from adjuvant chemotherapy.
VEGF expression has recently been related to clinical response to bevacizumab in tumors other than CRC [25] , and it has been suggested that, much as for other therapeutic strategies, apparent resistance to anti-VEGF therapies can occur, probably through hypoxia-triggered upregulation of other proangiogenic factors [26] . Alternatively, genetic polymorphisms might be responsible for different VEGF expression and variability in therapeutic response to bevacizumab. Counteracting such mechanisms of resistance by multitargeting alternative proangiogenic signaling circuits may improve the efficacy of antiangiogenic therapies.
One final issue that raised our attention was the strong correlation between CEA and VEGF content either in tumor biopsies or in normal mucosa. This observation raises another question, namely what causes the increased levels of VEGF and CEA expression in histologically normal mucosa from carcinoma patients versus histologically normal mucosa from healthy donors. Possible reasons are early genetic changes that may predispose a particular individual to develop neoplastic disease during his/her lifetime. Alternatively, increased VEGF or CEA expression might be the result of a paracrine phenomenon in which factors produced by carcinoma cells cause a phenotypic change of adjacent normal colonic mucosa. As the association between CEA and VEGF is concerned, we could hypothesize that CEA might be involved in the regulation of VEGF expression in CRC cancer, as recently demonstrated for other CEA-related cell adhesion molecules, namely CEACAM1 that was found to be one of the major effectors of VEGF in early microvessel formation and angiogenesis [27, 28] , supporting the growth of invasive tumors [29] . Otherwise, since both CEA and VEGF are overexpressed in the normal mucosa of CRC patients compared to that of healthy subjects, another plausible explanation for the correlation observed might be that both biomarkers could be regulated in an autocrine fashion by factors elaborated by neoplastic tissues in CRC patients.
We are aware that these hypotheses require detailed experimental evaluation before their ultimate significance can be determined. Nevertheless, we hope that our study will prompt investigators to design new studies to better understand the relationship between CEA and VEGF in the disease progression, as well as its contribution as a prognostic factor for CRC. Although our study may be limited by the small sample size, the results reported here strongly suggest that combined measurement of CEA and VEGF tumor tissue content might add useful prognostic information in the management of patients with CRC, and may help in the choice of more aggressive treatment and/or more strict follow-up procedures in a subgroup of patients who are at high risk of recurrence. New prospective studies specifically designed to address this issue are warranted.
